Thu, Sep 18, 2014, 8:25 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

The Walt Disney Company Message Board

yingand_yang 11 posts  |  Last Activity: Aug 19, 2014 2:13 PM Member since: Jun 29, 2006
  • yingand_yang by yingand_yang Aug 19, 2014 2:13 PM Flag

    Sprint’s S first move under new CEO Marcelo Claure, the introduction of a new pricing structure and pricing promotions, makes sense, at least in theory. The firm clearly needed to adjust pricing quickly in light of relatively poor “Framily” plan adoption, the result of pricing widely out of step with the market for accounts with three or more lines. While Sprint is taking a necessary step forward, the firm still has a long road ahead as it works to improve its financial performance. Ultimately, we still believe additional scale is needed to fundamentally improve Sprint’s competitive position; our moat rating is unchanged. We believe the stock is roug hly fairly valued. Sprint is joining rivals AT&T and Verizon in offering shared buckets of data capacity, moving away from its previous steadfast hold to unlimited data plans. However, Sprint’s plans offer roughly twice as much data capacity at each data price point than its rivals. The large size of the data buckets should showcase Sprint’s ability to utilize its massive spectrum portfolio to deliver data capacity over time. However, Sprint still has a long way to go in terms of network quality, as several key milestones in its network deployment have yet to be reached. Critically, the firm only expects to cover 100 million people with Spark (LTE service utilizing 2.5 GHz spectrum) by the end of the year. Also, like AT&T and Verizon, Sprint is offering deep discounts on voice and texting service to those customers that take... For the entire note, click here.
    Michael Hodel, CFA

  • yingand_yang by yingand_yang Aug 13, 2014 11:39 AM Flag

    by The Street from sell to hold.

  • Show me that Afrezza will sell and the PPS will go higher!

  • yingand_yang by yingand_yang Aug 11, 2014 10:23 PM Flag

    By partnering with Sanofi, MannKind has engaged a proven marketer in the global diabetes arena and one that can leverage the very attractive combination of Afrezza and a long-acting basal insulin," said Keith Markey, an analyst with Griffin Securities. He estimates MannKind's stock will be trading at $16.25 in one year, nearly twice its Monday closing price.

  • yingand_yang by yingand_yang Aug 11, 2014 12:51 PM Flag

    MannKind MNKD announced on Aug. 11 that it has entered into a worldwide licensing agreement with Sanofi to develop and commercialize its inhaled insulin Afrezza. The terms of the deal are attractive, and Sanofi represents an ideal partner, with its extensive experience and commercial infrastructure in the diabetes market. While we expected a deal with broadly similar terms, we are raising our fair value estimate slightly because of the reduced uncertainty about the commercial attractiveness of Afrezza and the timing of its launch. We are maintaining our no-moat and stable trend ratings.Under the agreement, Sanofi will be responsible for global commercial, regulatory, and development activities, and the companies will share global profits and losses, with Sanofi retaining 65% and MannKind receiving 35%. MannKind will also receive an upfront payment of $150 million and potential milestone payments of up to $775 million, based on regulatory and development targets, as well as sales thresholds. The companies plan to launch the drug in the U.S. in the first quarter of 2015.MannKind also announced its second-quarter results on Aug. 11, reporting a loss of $73.4 million, or $0.19 per share, and a cash balance of $41.2 million. Clearly the $150 million upfront payment allows the company to replenish its cash reserves, and Sanofi has agreed to advance to MannKind its share of the collaboration’s expenses up to $175 million, reducing MannKind’s near-term cash requirements.
    Stefan Quenneville, CFA

  • yingand_yang by yingand_yang Aug 11, 2014 12:44 PM Flag

    With a huge $44 billion deal, Kinder Morgan solves its growth problem. For years, Kinder Morgan Energy Partners KMP has struggled to increase distributions to unitholders as rapidly as peers, but the burden of incentive distribution rights that shifted nearly half of cash payouts to its general partner has limited distribution growth to roughly half the rate of EBITDA growth. We've been waiting for Kinder to address this overhang for some time, but we had been focused on KMP buying out its general partner, Kinder Morgan Inc. KMI, something the math just hasn't accommodated. The deal announced Sunday turns this on its head and takes advantage of the relative discount the market had assigned to KMP and other Kinder family master limited partnerships: General partner KMI will acquire the outstanding stock of KMP, Kinder Morgan Management KMR, and El Paso Pipeline Partners EPB, consolidating the midstream family into a single corporation. As announced, the deal values KMP and KMR at $90, spot on with our $90 fair value estimates, and values EPB at $39 per unit, a 7% premium to our $37 fair value estimate. Because this deal eliminates the incentive distribution structure entirely, we expect the combined KMI to be able to sustain more rapid dividend growth than our previous forecast, and we expect to raise our current $35 fair value estimate by 10%-15%. Because this is a majority-equity deal, we also expect to adjust our fair value estimates for KMP, KMR, and EPB to reflect a higher value for KMI.

  • yingand_yang by yingand_yang Aug 8, 2014 12:01 PM Flag

    Mutual fund wants out! A falling knife!

    Sentiment: Hold

  • yingand_yang yingand_yang Jul 15, 2014 4:00 PM Flag

    Check out the major holders on yahoo. That is the source I used.

  • are loaded up with MNKD shares! Top Institutions!

  • yingand_yang by yingand_yang Jul 15, 2014 2:17 PM Flag

    Just added more shares!

  • yingand_yang by yingand_yang Jul 2, 2014 12:37 PM Flag

    MannKind (MNKD) Stock Continues to Decline Wednesday
    BY Andrew Meola 07/02/14 - 12:20 PM EDT

    NEW YORK (TheStreet) -- MannKind (MNKD_) continued to decline Wednesday after news on Monday that the FDA had approved the biopharmaceutical company's inhaled insulin drug Afrezza.

    The stock surged by double digits on Monday but declined Tuesday after MLV & Co. downgraded the stock to "hold" from "buy." The firm is curbing its expectations for Afrezza until the next step in the process.

    "Our next immediate focus is the commercial partnership for Afrezza," the firm wrote in a research note. "Which pharma MNKD secures as a partner and partnership deal terms will be major factors in determining how the market (and stock) reacts. We expect partnership news in the next two to three months (but are hopeful it could come sooner), and note that we'll likely use that event as an opportunity to re-evaluate our views on the stock and Afrezza's prospects."

90.34+0.01(+0.01%)Sep 18 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.